A clinical study to assess if a new investigational medicinal product called JJP-1212 is safe, tolerable and able to induce a specific immune response in humans

2023-508661-33-00 Protocol JJP-1212-01-01 Human pharmacology (Phase I) - First administration to humans Authorised, recruiting

Start 29 May 2024 · Status Authorised, recruiting · 2 EU/EEA countries · 2 sites · Protocol JJP-1212-01-01

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Authorised, recruiting
Participants planned 76
Countries 2
Sites 2

Rheumatoid Arthritis

Key facts

Sponsor
Jjp Biologics Sp. z o.o.
Participant type
Healthy volunteers, Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Musculoskeletal Diseases [C05], Diseases [C] - Immune System Diseases [C20], Diseases [C] - Skin and Connective Tissue Diseases [C17]
Trial duration
29 May 2024 → ongoing
Decision date (initial)
2025-10-13
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Rheumatoid Arthritis

VersionLevelCodeTermSystem organ class
26.0 LLT 10048601 Linear IgA bullous dermatosis 10040785
28.0 LLT 10003268 Arthritis rheumatoid 10028395

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Jjp Biologics Sp. z o.o.

Sponsor organisation
Jjp Biologics Sp. z o.o.
Address
Ul. Ulica Bobrowiecka 6
City
Warsaw
Postcode
00-728
Country
Poland

Scientific contact point

Organisation
Jjp Biologics Sp. z o.o.
Contact name
Clinical Trials

Public contact point

Organisation
Jjp Biologics Sp. z o.o.
Contact name
Clinical Trials

Locations

2 EU/EEA countries · 2 investigational sites

By country

CountryMS statusPlanned subjectsSites
Bulgaria Authorised, recruitment pending 4 1
Poland Ongoing, recruiting 72 1
Rest of world 0

Investigational sites

Bulgaria

1 site · Authorised, recruitment pending
Alexandrovska University Hospital
Department of Dermatology and Venereology, Georgy Sofiiski Str 1, 1431, Sofia

Poland

1 site · Ongoing, recruiting
Mtz Clinical Research Powered By Pratia
Phase I unit, Ul. Gładka 22, 02-172, Warsaw

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Poland 2024-05-29 2024-06-24

Application history

5 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-02-14 Poland Acceptable with conditions
2024-05-20
2024-05-27
2 SUBSTANTIAL MODIFICATION SM-1 2025-01-08 Poland Acceptable
2025-02-24
2025-03-02
3 NON SUBSTANTIAL MODIFICATION NSM-4 2025-07-04 Poland Acceptable
2025-02-24
2025-07-04
4 SUBSEQUENT ADDITION OF MSC APP-4 2025-07-17 2025-10-13
5 SUBSTANTIAL MODIFICATION SM-2 2025-11-28 Poland Acceptable
2026-02-06
2026-03-13